Quincy, Massachusetts Clinical Trials

A listing of Quincy, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 102 clinical trials
CIML NK Cell in Head & Neck Cancer

This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This research study involves the following drugs and biologics: CIML NK donor cells IL-15 superagonist Ipilimumab

immunohistochemistry
biological therapy
neck cancer
ipilimumab
prednisone
Dana Farber Cancer Institute
 (7.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Lorlatinib Combinations in Lung Cancer

This research study is evaluating Lorlatinib in combination with Crizotinib or Binimetinib as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. This research study involves three study drugs. Lorlatinib Binimetinib Crizotinib

immunohistochemistry
traumatic injury
lung cancer
levetiracetam
progressive disease
Beth Israel Deaconess Medical Center
 (8.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

neurofibroma
cataract
schwartz
measurable disease
nf2 gene
Children's Hospital Boston (Site 725)
 (7.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +16 other locations
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing …

melanoma
hepatitis b surface antigen
endometrial adenocarcinoma
ipilimumab
stage iv non-small cell lung cancer
Massachusetts General Hospital Cancer Center
 (8.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +8 other locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

epidermal growth factor
erbb1
stage iv breast cancer
her2- breast cancer
breast cancer
Massachusetts General Hospital
 (8.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

solid tumour
solid tumor
kras g12c mutation
metastatic malignant solid tumor
kras
Dana Farber Cancer Institute
 (8.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +7 other locations
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

immunohistochemistry
bisphosphonate
menstrual period
granulocyte colony stimulating factor
g-csf
Dana-Farber Cancer Institute
 (8.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Randomized Controlled Trial of AppS to Home Monitor Your Asthma

The objective of this study is to design, implement, and evaluate the impact of an adapted health information technology(IT)-enabled practice model for asthma symptom monitoring using patient-reported outcomes (PROs) in a primary care setting. Adults over 18 years of age with asthma will be recruited at four primary care clinics …

Brigham & Women's Hospital
 (7.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Cisplatin+Pembrolizumab+RT in Vulvar Cancer

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)

endocrine therapy
absolute neutrophil count
conjugated bilirubin
cytotoxic chemotherapy
carcinoma
Massachusetts General Hospital Cancer Center
 (8.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Preoperative Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

Prior studies have shown that left ventricular assist device (LVAD) implantation commonly results in right ventricular failure (RVF). Right ventricular dysfunction and failure after LVAD implantation is known to increase morbidity and mortality and contribute to longer post-implant hospital length of stay. Since RVF is difficult to predict and can …

right ventricular failure
ventricular dysfunction
Massachusetts General Hospital
 (8.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location